Skip to Content
Søk Menu

Venetoclax plus obinutuzumab er den mest omkostningseffektive behandling af CLL uden del17p/TP53-mutationer

/ Matilde Slot
ASH22KLL Play the Video 3:30

Several interesting combinations of therapies with Calquence for patients with CLL

/ Matthew S. Davids
ASH22KLL Play the Video 3:14
Freya Bastrup

Electrochemotherapy for cutaneous tumors is a well-established treatment with a consistently high response rate

/ Freya Armstrong Bastrup
Hudcancer Play the Video 7:48

New combination shows promising efficacy in patients with triple-class refractory R/R multiple myeloma

/ Paul G. Richardson
ASH22Myelom Play the Video 2:58

Lower-risk myelodysplastic syndromes treated with Reblozyl, luspatercept – Real-world outcomes

/ Sudipto Mukherjee
ASH22 Play the Video 2:42

LBA ASH22: Significantly better overall survival in patients with B-lineage ALL treated with Blincyto, blinatumomab, as Consolidation Therapy

/ Mark Robert Litzow
ALLASH22 Play the Video 4:24

BCMA-targeted and CAR-T cells therapies for multiple myeloma give a very exciting future and new hope for the patients

/ Sagar Lonial
ASH22Myelom Play the Video 2:08

R/R Large B-cell Lymphoma: Interesting results from ASH 2022 for treatment with Yescarta (axicabtagene ciloleucel)

/ Frederick L. Locke
ASH22Lymfom Play the Video 2:12
Veerle Bergink

Mental health disorders during pregnancy and the postpartum period

/ Veerle Bergink
DepressionGraviditet Play the Video 8:02

microRNAs – future biomarkers in psoriasis?

/ Åshild Øksnevad Solvin
Psoriasis
Back to top